𝔖 Bobbio Scriptorium

✦ LIBER ✦

Pentafuside (T20), a novel inhibitor of HIV-1 fusion: Pharmacokinetics and in vivo efficacy: D. M. Lambert, T. Venetta, B. Dimassimo, S. Hopkins, P. L. Black1, O. L. Wood1, D. D. Broud1, M. Bacho1, S. C. Kunder1, S. Papermaster1, S. Barney, and M. A. Ussery1. Trimeris, Inc., Research Triangle Park, NC. and 1 U.S.F.D.A., Rockville, MD

Book ID: 113259447
Publisher: Elsevier Science
Year: 1996
Tongue: English
Weight: 130 KB
Volume: 30
Category: Article
ISSN: 0166-3542
DOI: 10.1016/0166-3542(96)80231-2

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Potent inhibition of HIV-1 replication i

Potent inhibition of HIV-1 replication in vivo by a novel inhibitor of HIV-1 fusion: Michael A. Ussery, Owen L. Wood, Dennis D. Broud, Matthew A. Bacho, Steven C. Kunder, Susan F. Papermaster, Dennis M. Lambert1, Shawn Barney1, and Paul L. Black. U.S.F.D.A., Rockville, MD, and 1Trimeris, Inc., Research Triangle Park, NC, USA

📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 119 KB

184 Pentafuside (T-20), a novel inhibito

184 Pentafuside (T-20), a novel inhibitor of HIV-1 fusion: Pharmacokinetics in rodents, monkeys and man: T. Venetta, B. DiMassimo, M.R. Johnson, D.M. Lambert, M.A. Recny, S. Hopkins and M. Saag* Trimeris, Inc., P. O. Box 13963, Research Triangle Park, NC 27709 *AIDS Outpatient Clinic, University of Alabama at Birmingham, Birmingham, Alabama 35294

📂 Article 📅 1997 🏛 Elsevier Science 🌐 English ⚖ 104 KB

Antiviral activity of the protease inhib

Antiviral activity of the protease inhibitor KNI-272 in vivo in the HIV-infected HuPBMC-SCID mouse model: Michael A. Ussery, Owen L. Wood, Dennis D. Broud, Matthew Bacho, Steven C. Kunder, Susan Papermaster, Yoshiaki Kiso1, and Paul L. Black. U.S.F.D.A., Rockville, MD, USA, and 1 Kyoto Pharmaceutical University, Kyoto, Japan

📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 130 KB

43 The discovery and general SAR studies

43 The discovery and general SAR studies of a novel class of potent non-nucleoside reverse transcriptase inhibitors: R. J. Ternansky1, J. M. Morin, Jr.1, C. Lopez1, C. J. Paget, Jr.1, F. W. Bell1, A. S. Cantrell1, S. R. Jaskunas1, C. L. Jordan1, M. D. Kinnick1, J. A. Palkowitz1, C. A. Parrish1, P. Pranc1, R. T. Vasileff1, S. J. West1, M. Hogberg2, P. Lind2, R. Noreen2, C. Sahlberg2, X.-X. Zhou2, L. Vrang2, C. Rydergard2, C. Ahgren2, B. Oberg2, and N. G. Johansson2. 1Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA; 2Medivir AB, Huddinge, Sweden

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 50 KB

45 Comparative efficacy of HIV inhibitor

45 Comparative efficacy of HIV inhibitors on cells infected with cell free HIV or cocultivated with HIV-infected cells: L. Vrang1, C. Rydergard1, C. Ahgren1, P. Engelhardt1, M. Hogberg1, J. Kangasmetsa1, P. Lind1, R. Noreen1, C. Sahlberg1, X.-X. Zhou1, N. G. Johansson1, C. Lopez2, J. M. Morin, Jr.2, R. J. Ternansky2, F. W. Bell2, C. L. Jordan2, M. D. Kinnick2, J. A. Palkowitz2, C. A. Parrish2, P. Pranc2, R. T. Vasileff2, S. J. West2, and B. Oberg1. 1Medivir AB, Huddinge, Sweden; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 83 KB

71 SAR studies optimizing HIV-1 inhibiti

71 SAR studies optimizing HIV-1 inhibiting activities of LY73497, a new series of non-nucleoside inhibitors of reverse transcriptase: P. Engelhardt1, M. Hoberg1, J. Kangametsa1, P. Lind1, R. Noreen1, C. Sahlberg1, X.-X. Zhou1, L. Vrang1, H. Zhang1, B. Oberg1, N. G. Johansson1, F. W. Bell2, A. S. Cantrell2, J. A. Palkowitz2, S. R. Jaskunas2, C. L. Jordan2, M. D. Kinnick2, J. M. Morin, Jr.2, C. A. Parrish2, P. Pranc2, R. J. Ternansky2, R. T. Vasileff2, and S. J. West2. 1Medivir AB, Huddinge, Sweden; 2Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, USA

📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 62 KB